These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1208 related items for PubMed ID: 16059627

  • 1. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study.
    Chesnut CH, Majumdar S, Newitt DC, Shields A, Van Pelt J, Laschansky E, Azria M, Kriegman A, Olson M, Eriksen EF, Mindeholm L.
    J Bone Miner Res; 2005 Sep; 20(9):1548-61. PubMed ID: 16059627
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis.
    Chen P, Miller PD, Recker R, Resch H, Rana A, Pavo I, Sipos AA.
    J Bone Miner Res; 2007 Aug; 22(8):1173-80. PubMed ID: 17451369
    [Abstract] [Full Text] [Related]

  • 4. Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women.
    Holloway L, Kohlmeier L, Kent K, Marcus R.
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1111-7. PubMed ID: 9100582
    [Abstract] [Full Text] [Related]

  • 5. Nasal salmon calcitonin blunts bone microstructure alterations in healthy postmenopausal women.
    Rizzoli R, Sigaud A, Azria M, Herrmann FR.
    Osteoporos Int; 2015 Jan; 26(1):383-93. PubMed ID: 25566730
    [Abstract] [Full Text] [Related]

  • 6. In vivo assessment of architecture and micro-finite element analysis derived indices of mechanical properties of trabecular bone in the radius.
    Newitt DC, Majumdar S, van Rietbergen B, von Ingersleben G, Harris ST, Genant HK, Chesnut C, Garnero P, MacDonald B.
    Osteoporos Int; 2002 Jan; 13(1):6-17. PubMed ID: 11878456
    [Abstract] [Full Text] [Related]

  • 7. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
    Cheung AM, Tile L, Cardew S, Pruthi S, Robbins J, Tomlinson G, Kapral MK, Khosla S, Majumdar S, Erlandson M, Scher J, Hu H, Demaras A, Lickley L, Bordeleau L, Elser C, Ingle J, Richardson H, Goss PE.
    Lancet Oncol; 2012 Mar; 13(3):275-84. PubMed ID: 22318095
    [Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover.
    Tankó LB, Bagger YZ, Alexandersen P, Devogelaer JP, Reginster JY, Chick R, Olson M, Benmammar H, Mindeholm L, Azria M, Christiansen C.
    J Bone Miner Res; 2004 Sep; 19(9):1531-8. PubMed ID: 15312255
    [Abstract] [Full Text] [Related]

  • 9. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure.
    Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, García-Hernandez PA, Supronik J, Lewiecki EM, Ochoa L, Miller P, Hu H, Mesenbrink P, Hartl F, Gasser J, Eriksen EF.
    J Bone Miner Res; 2008 Jan; 23(1):6-16. PubMed ID: 17892374
    [Abstract] [Full Text] [Related]

  • 10. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography.
    Borah B, Dufresne TE, Chmielewski PA, Johnson TD, Chines A, Manhart MD.
    Bone; 2004 Apr; 34(4):736-46. PubMed ID: 15050906
    [Abstract] [Full Text] [Related]

  • 11. Interrelationships between bone microarchitecture and strength in ovariectomized monkeys treated with teriparatide.
    Chen P, Jerome CP, Burr DB, Turner CH, Ma YL, Rana A, Sato M.
    J Bone Miner Res; 2007 Jun; 22(6):841-8. PubMed ID: 17352652
    [Abstract] [Full Text] [Related]

  • 12. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.
    Binkley N, Bolognese M, Sidorowicz-Bialynicka A, Vally T, Trout R, Miller C, Buben CE, Gilligan JP, Krause DS, Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) Investigators.
    J Bone Miner Res; 2012 Aug; 27(8):1821-9. PubMed ID: 22437792
    [Abstract] [Full Text] [Related]

  • 13. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.
    Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, Stock JL, Song J, Qu Y, Kulkarni PM, Siddhanti SR, Wong M, Cummings SR, Continuing Outcomes Relevant to Evista (CORE) Investigators.
    J Bone Miner Res; 2005 Sep; 20(9):1514-24. PubMed ID: 16059623
    [Abstract] [Full Text] [Related]

  • 14. In vivo assessment of trabecular bone structure using fractal analysis of distal radius radiographs.
    Majumdar S, Link TM, Millard J, Lin JC, Augat P, Newitt D, Lane N, Genant HK.
    Med Phys; 2000 Nov; 27(11):2594-9. PubMed ID: 11128312
    [Abstract] [Full Text] [Related]

  • 15. Effects of odanacatib on the radius and tibia of postmenopausal women: improvements in bone geometry, microarchitecture, and estimated bone strength.
    Cheung AM, Majumdar S, Brixen K, Chapurlat R, Fuerst T, Engelke K, Dardzinski B, Cabal A, Verbruggen N, Ather S, Rosenberg E, de Papp AE.
    J Bone Miner Res; 2014 Aug; 29(8):1786-94. PubMed ID: 24643905
    [Abstract] [Full Text] [Related]

  • 16. In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography.
    Boutroy S, Bouxsein ML, Munoz F, Delmas PD.
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6508-15. PubMed ID: 16189253
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
    McClung MR, Wasnich RD, Recker R, Cauley JA, Chesnut CH, Ensrud KE, Burdeska A, Mills T, Oral Ibandronate Study Group.
    J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
    [Abstract] [Full Text] [Related]

  • 19. Treatment of post-menopausal osteoporosis with recombinant human growth hormone and salmon calcitonin: a placebo controlled study.
    Gonnelli S, Cepollaro C, Montomoli M, Gennari L, Montagnani A, Palmieri R, Gennari C.
    Clin Endocrinol (Oxf); 1997 Jan; 46(1):55-61. PubMed ID: 9059558
    [Abstract] [Full Text] [Related]

  • 20. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
    Tascioglu F, Colak O, Armagan O, Alatas O, Oner C.
    Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 61.